Intratus

Executive Summary

Intratus, Inc. is a privately held, clinical-stage life sciences company based in San Diego, focused on developing a patented, non-invasive, sustained-release transdermal drug delivery platform for ophthalmic diseases. Founded in 2005, the company aims to address the limitations of traditional eye drops and injections by enabling controlled, long-term drug delivery to all segments of the eye. Intratus's technology has the potential to improve patient compliance and treatment outcomes for conditions such as glaucoma, dry eye, and retinal disorders. Currently in Phase 1 development, the company is advancing its lead candidates through preclinical and early clinical studies, though specific financial and operational details remain undisclosed due to its private status. The company's transdermal platform represents a novel approach in ocular drug delivery, a market with significant unmet need. While Intratus has not publicly disclosed total funding or valuation, its long development timeline (over 20 years since founding) suggests a cautious but persistent R&D strategy. Key risks include the technical challenges of sustained delivery to ocular tissues and the competitive landscape dominated by established players. However, if successful, Intratus could offer a differentiated product with advantages in convenience and efficacy. Conviction is moderate given the early stage and lack of recent public data.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1/2 Clinical Trial for Lead Ophthalmic Candidate70% success
• Q4 2026Partnership or Licensing Agreement for Platform Technology40% success